Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05543915 · ClinicalTrials.gov registry record · NA

Cognitive Markers in Prodromal MS

A NA study of Multiple Sclerosis, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT05543915: Completed NA study of Multiple Sclerosis, sponsored by NYU Langone Health.

NCT05543915 is a NA study of Multiple Sclerosis that has completed, run by NYU Langone Health. The registered enrollment target is 60 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05543915, a NA study of Multiple Sclerosis, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The focus of this work is the evaluation of a measure of cognitive functioning- intra-individual variability (IIV) - derived from a computer-based continuous reaction time (RT) task (Cogstate) as an early marker of prodromal MS.

Primary Outcome

CMRO2 is the amount of O2 the brain consumes per unit of time (in μmol O2/100g tissue per minute). To quantify absolute CMRO2, both TRUST MRI for quantification of venous oxygenation (Yv) and phase contrast (PC) MRI for quantification of total blows are needed. The total scan time for CMRO2 MRI is approximately 4 minutes.

Conditions Studied

Multiple Sclerosis

Interventions

  • DEVICE Active tDCS

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2022-02-09
Est. Completion 2024-06-20
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT05543915 record still lists

NCT05543915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Active tDCS is the first listed.

NCT05543915 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05543915 about?

NCT05543915 is a clinical study titled "Cognitive Markers in Prodromal MS". The focus of this work is the evaluation of a measure of cognitive functioning- intra-individual variability (IIV) - derived from a computer-based continuous reaction time (RT) task (Cogstate) as an early marker of prodromal MS.

What is the current status of trial NCT05543915?

This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2022-02-09. Estimated completion is 2024-06-20.

What conditions does trial NCT05543915 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT05543915?

The interventions under investigation include: Active tDCS (DEVICE).

Who is sponsoring clinical trial NCT05543915?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05543915 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05543915's enrollment target sits among peer trials

60 159th of 315 higher than 146 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05543915, the US trial registry maintained by the National Library of Medicine. NCT05543915 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.